Related Experiment Videos
Sequential coronary artery bypass utilizing the internal mammary artery
1Department of Surgery, Ochsner Clinic, New Orleans, LA.
The Journal of Cardiovascular Surgery
|March 1, 1988
Summary
Sequential internal mammary artery (IMA) grafting is a feasible technique for coronary artery bypass surgery. This study found all patients lived and remained angina-free for 3-5 years, with no perioperative heart attacks.
Area of Science:
- Cardiovascular Surgery
- Cardiac Surgery
- Vascular Grafting
Background:
- Coronary artery disease necessitates bypass grafting for revascularization.
- The left internal mammary artery (IMA) is a preferred graft for coronary artery bypass grafting (CABG).
- Sequential grafting techniques aim to optimize revascularization with limited arterial conduits.
Purpose of the Study:
- To evaluate the technical feasibility and early clinical outcomes of using the left internal mammary artery (IMA) as a sequential bypass graft.
- To establish guidelines for the optimal application of sequential IMA grafting in coronary artery bypass surgery.
Main Methods:
- Fifty consecutive patients undergoing CABG received sequential bypass grafting using the IMA.
- The IMA was sequentially anastomosed to two or more diseased coronary arteries.
- Specific technical guidelines were followed, including prioritizing the left anterior descending/diagonal arteries and performing distal anastomosis first.
Main Results:
- No perioperative myocardial infarctions occurred in the 50 patients.
- All 50 patients were alive and remained free of angina at 3-5 year follow-up.
- Postoperative angiograms in 11 patients showed no stenosis, occlusion, or late adverse effects.
Conclusions:
- Sequential IMA grafting is a technically feasible and safe procedure for coronary artery bypass surgery.
- Adherence to specific technical guidelines, such as avoiding kinks and prioritizing distal anastomoses, is crucial for success.
- This technique offers excellent long-term clinical outcomes, with patients remaining free of angina and demonstrating patent grafts.